期刊文献+

树突状细胞体外诱导方案的对比 被引量:1

下载PDF
导出
摘要 目的探讨并比较不同细胞因子组合、诱导时间对树突状细胞(DC)体外诱导、成熟,分泌细胞因子水平和刺激淋巴细胞增殖能力的影响,为建立DC体外高效、规模化培育体系提供依据。方法分离健康人外周血单个核细胞(PBMC),贴壁法获得DC前体细胞,用白细胞介素4(IL-4)和粒细胞巨噬细胞集落刺激因子(GM-CSF)诱导2 d,将其分为6组。A组加入肿瘤坏死因子α(TNF-α)、IL-1α和前列腺素E2(PGE2);B组加入α干扰素(IFN-α);C组加入脂多糖(LPS);3组细胞继续培育2 d。D^F组细胞先进行1/3体积换液,24 h后,分别再加入上述A^C组的成熟因子,再继续诱导2 d。分别收获各组上清和细胞,进行细胞计数,采用流式细胞术进行表型分析;采用ELISA检测各组DC分泌IL-12p70的水平、采用细胞增殖检测试剂盒刺激淋巴细胞增殖的能力。结果 6组体外诱导体系均能培育出形态学类似DC的细胞,DC数量与纯度(均达到96%以上),各组间无显著性差异。A组与D组比较:CD40、CD80、CD83、CD86共刺激分子表达水平相近,但D组DC分泌IL-12p70水平高于A组;B组与E组比较:E组DC的CD86表达水平显著高于B组,CD80表达量略高于B组,2组DC分泌IL-12p70的水平相近;C组与F组比较:CD40、CD80、CD83、CD86共刺激分子表达水平和分泌IL-12p70的水平均相近。6组DC刺激淋巴细胞增殖水平均相近。三种不同成熟因子(组合)比较:B组DC共刺激分子CD80水平明显低于C组和A组,且IL-12p70分泌水平最低,而C组和A组共刺激分子表达水平与IL-12p70分泌水平相近。结论 TNF-α、IL-1α和PGE-2三种细胞因子联合以及LPS可有效地诱导DC表达高水平免疫共刺激分子、分泌高水平IL-12p70。
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2015年第12期1655-1658,共4页 Chinese Journal of Cellular and Molecular Immunology
  • 相关文献

参考文献25

  • 1Gelao L, Criscitiello C, Esposito A, et al. Dendritic cell-based vaccines: clinical applications in breast cancer [ J ]. Immunotherapy, 2014, 6(3) : 349 -360.
  • 2Apostolopulos V, Pietersz G A, Tsibanis A, et al. Dendritic cell immunotherapy: clinical outcomes [ J/OL]. Clin Transl Immunology, 2014, 3(7): e21. doi: 10. 1038/cti. 2014. 14. eCollection 2014.
  • 3Weber J S. Current perspectives on immunotherapy [ J ]. Semin Oncol, 2014, 41 (Suppl 5) : S14 -S29.
  • 4Sharma A, Koldovsky U, Xu S, et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma insitu[J]. Cancer, 2012, 118(17):4354-4362.
  • 5Bakocevic N, Worbs T, Davalos-Misslitz A, et al. T cell-dendritic cell interation dynamics during the induction of respiratory tolerance and immunity[J]. J Imnmnol, 2010, 184(3) : 1317 -1327.
  • 6Anguile S, Smits E L, Lion E, et al. Clinical use of dendritic cells for cancer therapy [ J/OL ]. Lancet Oncol, 2014, 15 ( 7 ) : e257 - e267. doi. 10. 1016/S1470 - 2045 ( 13 ) 70585 - 0.
  • 7Declerk S, Vansteenkiste J. Immunotherapy for lung cancer : ongoing clinical trials[ J].Future Oncol, 2014, 10( 1 ) : 91 -105.
  • 8刘方方,谢军平.以树突状细胞为基础的肿瘤免疫治疗策略研究进展[J].细胞与分子免疫学杂志,2014,30(12):1338-1340. 被引量:8
  • 9Xie Z X, Zhang H L, Wu X J, et al. Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis [ J/OL ]. Mediators Inflamm, 2015, 2015: 513295. doi: 10. 1155/2015/ 513295. Epub 2015 Jan 29.
  • 10杨华安,刘敦煌,苟欣.树突状细胞致免疫耐受的研究进展[J].山东医药,2014,54(13):87-89. 被引量:2

二级参考文献74

  • 1高伟生,罗荣城,马树东,尤长宣,吕成伟.人外周血树突状细胞的分离与鉴定[J].中国组织工程研究与临床康复,2007,11(11):2105-2108. 被引量:3
  • 2Radford KJ,Caminschi I. New generation of dendritic cell vac-cines [J] . Hum Vaccin Immunother, 2013 , 9(2) [ Epub aheadof print].
  • 3Cintolo JA,Datta J,Mathew SJ,et al. Dendritic cell-based vac-cines :Barriers and opportunities [ J]. Future Oncol,2012,8(10) ; 1273-1299.
  • 4Mantia-Smaldone GM, Chu CS. A review of dendritic cell therapyfor cancer: Progress and challenges [J]. BioDrugs, 2013 [Epubahead of print].
  • 5Kalinski P, Muthuswamy R, Urban J. Dendritic cells in cancerimmunotherapy: Vaccines and combination immunotherapies [J].Expert Rev Vaccines, 2013,12(3) : 285-295.
  • 6Gattinoni L, Powell DJ, Rosenberg SA, et al. Adoptive immuno-therapy for cancer: Building on success [ J]. Nat Rev Immunol,2006,6(5):383-393.
  • 7Koido S, Homma S, Okamoto M, et al. Combined TLR2/4-acti-vated dendritic/ tumor cell fusions induce augmented cytotoxic Tlymphocytes [ J]. PLoS One, 2013 , 8(3) : e59280.
  • 8Cui H, Zhang W, Hu W, et al. Recombinant mammaglobin a ad-enovirus-infected dendritic cells induce mammaglobin a-specificCD8 + cytotoxic T lymphocytes against breast cancer cells in vitro[J]. PLoS One, 2013, 8(5): e63055.
  • 9Kalantari T, Kamali-Sarvestani E, Ciric B, et al. Generation ofimmunogenic and tolerogenic clinical-grade dendritic cells [ J].Immunol Res, 2011,51(2/3) : 153-160.
  • 10Dong R, Moulding D, Himoudi N, et al. Cells with dendritic cellmorphology and immunophenotype, binuclear morphology, andimmunosuppressive function in dendritic cell cultures [ J]. CellImmunol, 2011, 272 (1) ; 1-10.

共引文献24

同被引文献12

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部